Soleno Therapeutics (SLNO) stock jumped over 32% in yesterday’s after-hours trading. The surge came after the company ...

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) today and set a price target of ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

Soleno Therapeutics, Inc.’s SLNO share price has surged by 37.61%, which has investors questioning if this is right time to ...

Shares of Soleno Therapeutics jumped 40% in morning trading on Thursday, after the company's drug for a rare metabolic condition became the first such treatment to receive U.S. regulatory nod.

Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) shares were up 3.9% during trading on Friday after Stifel Nicolaus ...

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...

Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...